Immunotherapeutic potential in murine tumor models of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose.
The systemic administration of multiple, nontoxic doses of polyinosinic-polycytidylic acid and poly-L-lysine solubilized by carboxymethylcellulose [poly(I,C)-LC] eradicated established experimental and spontaneous pulmonary metastases. Optimal immunotherapy was schedule dependent, requiring three to five injections of poly(I,C)-LC per week for a minimum of 4 weeks; in addition, therapeutic efficiency was partially dosage independent. Immunotherapy by poly(I,C)-LC was found to be limited by tumor burden, although when combined with chemotherapy as a debulking regimen it resulted in increased survival with protocols in which poly(I,C)-LC alone was insufficient. These data suggest that the systemic administration of poly(I,C)-LC may provide a successful adjuvant therapeutic modality against cancer metastasis.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D002266:Carboxymethylcellulose Sodium / Q000008:administration & dosage / Q000627:therapeutic use* / Q000031:analogs & derivatives; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D007167:Immunotherapy; D007369:Interferon Inducers / Q000627:therapeutic use*; D008297:Male; D008747:Methylcellulose / Q000031:analogs & derivatives*; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D011070:Poly I-C / Q000008:administration & dosage / Q000627:therapeutic use*; D011107:Polylysine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000031:analogs & derivatives
D000276:Adjuvants, Immunologic; D007369:Interferon Inducers; D010455:Peptides; D011107:Polylysine; C019531:poly ICLC; D003520:Cyclophosphamide; D008747:Methylcellulose; D002266:Carboxymethylcellulose Sodium; D011070:Poly I-C